BridgeBio Announces Clinical Collaboration With Amgen To Study BBP-398
- First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with the KRAS G12C mutation
PALO ALTO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- BridgeBio